Skip to main content

Free Content Cost-effectiveness of a new interferon-based blood assay, QuantiFERON®-TB Gold, in screening tuberculosis contacts

Download Article:
 Download
(PDF 372.861328125 kb)
 

Abstract:

BACKGROUND: Recent approval of interferon-gamma release assays that are more specific for Mycobacterium tuberculosis has given new options for the diagnosis of latent tuberculosis infection (LTBI).

OBJECTIVE: To assess the cost-effectiveness of Quanti-FERON®-TB Gold (QFT-G) vs. the tuberculin skin test (TST) in diagnosing LTBI in contacts of active TB cases using a decision analytic Markov model.

METHODS: Three screening strategies—TST alone, QFT-G alone and sequential screening of TST then QFT-G—were evaluated. The model was further stratified according to ethnicity and bacille Calmette-Guérin (BCG) vaccination status. Data sources included published studies and empirical data. Results were reported in terms of the incremental net monetary benefit (INMB) of each strategy compared with the baseline strategy of TST-based screening in all contacts.

RESULTS: The most economically attractive strategy was to administer QFT-G in BCG-vaccinated contacts, and to reserve TST for all others (INMB CA$3.70/contact). The least cost-effective strategy was QFT-G for all contacts, which resulted in an INMB of CA$−11.50 per contact. Assuming a higher prevalence of recent infection, faster conversion of QFT-G, a higher rate of TB reactivation, reduction in utility or greater adherence to preventive treatment resulted in QFT-G becoming cost-effective in more subgroups.

CONCLUSIONS: Selected use of QFT-G appears to be cost-effective if used in a targeted fashion.

Keywords: QuantiFERON TB-Gold; contacts; cost-effectiveness analysis; interferon gamma release assays; tuberculosis

Document Type: Regular Paper

Affiliations: 1: University of British Columbia, Vancouver, British Columbia, Canada; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada 2: University of British Columbia, Vancouver, British Columbia, Canada; and Centre for Health Evaluation and Outcome Sciences, Vancouver, British Columbia, Canada 3: University of British Columbia, Vancouver, British Columbia, Canada 4: University of British Columbia, Vancouver, British Columbia, Canada; and British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada 5: University of British Columbia, Vancouver, British Columbia, Canada; and Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

Publication date: 2008-12-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more